<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1510200211
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Olsar Plus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        70.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Olsar Plus&trade; contains two active substances , Olmesartan medoxomil and<br />Hydrochlorothiazide, that are used to treat high blood pressure<br />(hypertension):<br />&bull; Olmesartan medoxomil is one of a group of medicines called angiotensin<br />II-receptor antagonists. It lowers blood pressure by relaxing the blood<br />vessels.<br />&bull; Hydrochlorothiazide is one of a group of medicines called thiazide<br />diuretics (&ldquo;water tablets&rdquo;). It lowers blood pressure by helping the body to<br />get rid of extra fluid by making your kidneys produce more urine.<br />You will only be given Olsar Plus&trade; if Olsar&trade; (Olmesartan medoxomil)<br />alone has not adequately controlled your blood pressure. When given<br />together, the two active substances in Olsar Plus&trade; help to lower blood<br />pressure more than if either of them were given alone.<br />You may already be taking medicines to treat your high blood pressure, but<br />your doctor may want you to take Olsar Plus&trade; to lower it more.<br />High blood pressure can be controlled with medicines such as<br />Olsar Plus&trade; tablets. Your doctor has probably also recommended that you<br />make some changes in your lifestyle to help lower your blood pressure (for<br />example losing weight, giving up smoking, reducing the amount of alcohol<br />you drink and reducing the amount of salt in your diet). Your doctor may<br />also have urged you to take regular exercise, such as walking or swimming.<br />It is important to follow this advice from your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Olsar Plus&trade;:<br />&bull; if you are allergic to Olmesartan medoxomil or Hydrochlorothiazide, or<br />any of the other ingredients of this medicine (listed in section 6) or<br />substances similar to Hydrochlorothiazide (sulfonamides)<br />&bull; if you are more than 3 months pregnant (It is also better to avoid Olsar<br />Plus&trade; in early pregnancy-see pregnancy section)<br />&bull; if you have kidney problems<br />&bull; if you have diabetes or impaired kidney function and you are treated with<br />a blood pressure lowering medicine containing aliskiren<br />&bull; if you suffer from low potassium, low sodium, high calcium or high uric<br />acid levels in the blood (with symptoms of gout or kidney stones) that do<br />not get better when treated<br />&bull; if you suffer from moderate or severe liver problems or yellowing of the<br />skin and eyes (jaundice) or problems with drainage of the bile from the<br />gallbladder (biliary obstruction e.g. gallstones)<br />If you think any of these apply to you, or you are unsure, do not take the<br />tablets. Talk to your doctor first and follow the advice given.<br />Warnings and precautions<br />Talk to your doctor before using Olsar Plus&trade;.<br />Before you take the tablets, tell your doctor if you are taking any of the<br />following medicines used to treat high blood pressure:<br />&bull; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular<br />if you have diabetes-related kidney problems.<br />&bull; aliskiren<br />Your doctor may check your kidney function, blood pressure, and the<br />amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Olsar Plus&trade;&rdquo;.<br />Before you take the tablets, tell your doctor if you have any of the<br />following health problems:<br />&bull; Kidney transplant<br />&bull; Liver diseases<br />&bull; Heart failure or problems with your heart valves or heart muscles<br />&bull; Vomiting (being sick) or diarrhoea which is severe or it goes on for<br />several days<br />&bull; Treatment with high doses of water tablets (diuretics) or if you are on a<br />low salt diet<br />&bull; Problems with your adrenal glands (e.g. primary aldosteronism)<br />&bull; Diabetes<br />&bull; Lupus erythematosus (an autoimmune disease)<br />&bull; Allergies or asthma<br />&bull; If you have had skin cancer or if you develop an unexpected skin lesion<br />during the treatment. Treatment with Hydrochlorothiazide, particularly<br />long term use with high doses, may increase the risk of some types of skin<br />and lip cancer (non-melanoma skin cancer). Protect your skin from sun<br />exposure and UV rays while taking Olsar Plus&trade;.<br />Contact your doctor if you experience any of the following symptoms:<br />&bull; diarrhoea that is severe, persistent and causes substantial weight loss.<br />Your doctor may evaluate your symptoms and decide on how to continue<br />your blood pressure medication.<br />&bull; decrease in vision or eye pain. These could be symptoms of an increase of<br />pressure in your eye and can happen within hours to weeks of taking<br />Olsar Plus&trade;. This can lead to permanent vision impairment, if not treated.<br />Your doctor may want to see you more often and do some tests if you have<br />any of these conditions.<br />Olsar Plus&trade; may cause a rise in blood fat levels and uric acid levels (the<br />cause of gout &ndash; painful swelling of the joints). Your doctor will probably<br />want to do a blood test from time to time to check these.<br />It may change the levels of certain chemicals in your blood called<br />electrolytes. Your doctor will probably want to do a blood test from time to<br />time to check these. Signs of electrolyte changes are: thirst, dryness of the<br />mouth, muscle pain or cramps, tired muscles, low blood pressure<br />(hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea,<br />vomiting, less need to pass urine, a rapid heart rate. Tell your doctor if<br />you notice these symptoms.<br />As with any medicine which reduces blood pressure, an excessive drop in<br />blood pressure in patients with blood flow disturbances of the heart or brain<br />could lead to a heart attack or stroke. Your doctor will therefore check your<br />blood pressure carefully.<br />If you are due to have tests for parathyroid function, you should stop taking<br />Olsar Plus&trade; before these tests are carried out.<br />If you are a sports person, this medicine could change the results of an<br />anti-dope test to make it positive.<br />You must tell your doctor if you think that you are (or might become)<br />pregnant. Olsar Plus&trade; is not recommended in early pregnancy, and<br />pregnant, as it may cause serious harm to your baby (see section)<br />Children and adolescents<br />Olsar Plus&trade; is not recommended for children and adolescents under the age<br />of 18.<br />Other medicines and Olsar Plus&trade;<br />Tell your doctor or pharmacist if you are using, have recently used or might<br />use any other medicines.<br />In particular, tell your doctor or pharmacist about any of the following:<br />&bull; Other blood pressure lowering medicines (anti-hypertensives), as the<br />effect of Olsar Plus&trade; can be increased.<br />Your doctor may need to change your dose and/or to take other<br />precautions:<br />If you are taking an ACE-inhibitor or aliskiren (see also information under<br />the headings &ldquo;Do not take Olsar Plus&trade;&rdquo; and &ldquo;Warnings and precautions&rdquo;).<br />&bull; Medicines which may alter the levels of potassium in your blood if used<br />at the same time as Olsar Plus&trade;. These include:<br />- potassium supplements (as well as salt substitutes containing potassium)<br />- water tablets (diuretics)<br />- heparin (for thinning the blood)<br />- laxatives<br />- steroids<br />- adrenocorticotrophic hormone (ACTH)<br />- carbenoxolone (a medicine used to treat mouth and stomach ulcers)<br />- penicillin G sodium (also called benzylpenicillin sodium, an antibiotic)<br />- certain pain killers such as aspirin or salicylates<br />&bull; Lithium (a medicine used to treat mood swings and some types of<br />depression) used at the same time as Olsar Plus&trade; may increase the toxicity<br />of lithium. If you have to take lithium, your doctor will measure your<br />lithium blood levels.<br />&bull; Non-steroidal anti-inflammatory (NSAIDs) medicines (medicines used to<br />relieve pain, swelling and other symptoms of inflammation, including<br />arthritis) used at the same time as Olsar Plus&trade; may increase the risk of<br />kidney failure and the effect of Olsar Plus&trade; can be decreased by NSAIDs.<br />&bull; Sleeping tablets, sedatives and anti-depressant medicines, as using these<br />medicines together with Olsar Plus&trade; may cause a sudden drop in blood<br />pressure when standing up.<br />&bull; Certain medicines such as baclofen and tubocurarine, used to relax<br />muscles.<br />&bull; Amifostine and some other drugs used to treat cancers, such as<br />cyclophosphamide or methotrexate.<br />&bull; Colestyramine and colestipol, medicines for lowering blood fat levels.<br />&bull; Colesevelam hydrochloride, a drug that lowers the level of cholesterol in<br />your blood, as the effect of Olsar Plus&trade; may be decreased. Your doctor<br />may advise you to take Olsar Plus&trade; at least 4 hours before colesevelam<br />hydrochloride.<br />&bull; Anticholinergic agents, such as atropine and biperiden.<br />&bull; Drugs such as thioridazine, chlorpromazine, levomepromazine,<br />trifluoperazine, cyamemazine, s ulpiride, amis ulpride, pimozide,<br />sultopride, tiapride, droperidol or haloperidol, used to treat certain<br />psychiatric disorders.<br />&bull; Certain medicines such as quinidine, hydroquinidine, disopyramide,<br />amiodarone, sotalol or digitalis, used to treat heart problems.<br />&bull; Medicines such as mizolastine, pentamidine, terfenadine, dofetilide,<br />ibutilide or erythromycin injections, which may change the heart rhythm.<br />&bull; Oral anti-diabetic medicines, such as metformin, or insulin, used to lower<br />blood sugar.<br />&bull; Beta-blockers and diazoxide, medicines used to treat high blood pressure<br />or low blood sugar, respectively, as Olsar Plus&trade; can enhance their<br />blood-sugar-increasing effect.<br />&bull; Methyldopa, a medicine used to treat high blood pressure.<br />&bull; Medicines such as noradrenaline, used to increase blood pressure and<br />slow heart rate.<br />&bull; Diphemanil, used to treat a slow heartbeat or reduce sweating.<br />&bull; Medicines such as probenecid, sulfinpyrazone and allopurinol, used to<br />treat gout.<br />&bull; Calcium supplements.<br />&bull; Amantadine, an anti-viral drug.<br />&bull; Ciclosporin, a medicine used to stop rejection of organ transplants.<br />&bull; Certain antibiotics called tetracyclines or sparfloxacin.<br />&bull; Amphotericin, a medicine used to treat fungal infections.<br />&bull; Certain antacids, used to treat too much stomach acid, such as aluminium<br />magnesium hydroxide, as the effect of Olsar Plus&trade; can be slightly<br />decreased.<br />&bull; Cisapride, used to increase food movement in the stomach and gut.<br />&bull; Halofantrine, used for malaria.<br />Olsar Plus&trade; with food and drink<br />Olsar Plus&trade; can be taken with or without food.<br />Take care when drinking alcohol while you are taking Olsar Plus&trade;, as some<br />people feel faint or dizzy. If this happens to you, do not drink any alcohol,<br />including wine, beer or alcopops.<br />Black patients<br />As with other similar drugs the blood pressure lowering effect of<br />Olsar Plus&trade; is somewhat less in black patients.<br />Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant.<br />Your doctor will normally advise you to stop taking Olsar Plus&trade; before you<br />become pregnant or as soon as you know you are pregnant and will advise<br />you to take another medicine instead of Olsar Plus&trade;.<br />Olsar Plus&trade; is not recommended during pregnancy, and must not be taken<br />when more than 3 months pregnant, as it may cause serious harm to your<br />baby if it is used after the third month of pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Olsar Plus&trade; is not recommended for mothers who are breast-feeding, and<br />your doctor may choose another treatment for you if you wish to<br />breast-feed.<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />Driving and using machines<br />You may feel sleepy or dizzy while being treated for your high blood<br />pressure. If this happens, do not drive or use machines until the symptoms<br />wear off. Ask your doctor for advice.</p><p>Olsar Plus&trade; contains lactose<br />This medicine contains lactose (a type of sugar). If you have been told by<br />your doctor that you have an intolerance to some sugars, contact your<br />doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />The recommended dose is one Olsar Plus&trade; 40 mg/12.5 mg tablet a day.<br />However, if your blood pressure is not controlled, your doctor may decide<br />to change your dose to one Olsar Plus&trade; 40 mg/25 mg tablet a day.<br />Swallow the tablet with water. If possible, you should take your dose at the<br />same time each day, for example at breakfast time. It is important to<br />continue to take Olsar Plus&trade; until your doctor tells you to stop.<br />If you take more Olsar Plus&trade; than you should<br />If you take more tablets than you should, or if a child accidentally swallows<br />one or more, go to your doctor or nearest accident and emergency (A&amp;E)<br />department immediately and take your medicine pack with you.<br />If you forget to take Olsar Plus&trade;<br />If you forget to take a dose, take your normal dose on the following day as<br />usual. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Olsar Plus&trade;<br />It is important to continue to take Olsar Plus&trade; unless your doctor tells you<br />to stop.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />However, the following two side effects can be serious:<br />&bull; Allergic reactions that may affect the whole body, with swelling of the<br />face, mouth and/or voice box (larynx) together with itching and rash may<br />occur rarely. If this happens, stop taking Olsar Plus&trade; and contact your<br />doctor immediately.<br />&bull; Olsar Plus&trade; can cause the blood pressure to fall too low in susceptible<br />individuals or as the result of an allergic reaction. Light-headedness or<br />fainting may occur uncommonly. If this happens, stop taking<br />Olsar Plus&trade;, contact your doctor immediately and lie down flat.<br />Olsar Plus&trade; is a combination of two active substances and the following<br />information firstly gives the other side effects reported so far with the<br />combination Olsar Plus&trade; (besides those already mentioned above) and,<br />secondly, those which are known about for the separate active substances.<br />These are the other side effects known about so far with Olsar Plus&trade;:<br />If these side effects occur, they are often mild and you do not need to stop<br />your treatment.<br />Common side effects (may affect up to 1 in 10 people):<br />Dizziness, weakness, headache, tiredness, chest pain, swelling of ankles,<br />feet, legs, hands or arms.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />Fluttering of the heartbeat (palpitations), rash, eczema, vertigo, cough,<br />indigestion, abdominal pain, nausea, vomiting, diarrhoea, muscle cramps<br />and muscular pain, pain in joints, arms and legs, back pain, erection<br />difficulties in men, blood in urine.<br />Some changes in blood test results have also been seen uncommonly<br />and include:<br />Rise in blood fat levels, rise in blood urea or uric acid, rise in creatinine,<br />rise or decrease in blood potassium levels, rise in blood calcium levels, rise<br />in blood sugar, increase in levels of liver function. Your doctor will know<br />about these from a blood test and will tell you if you need to do anything.<br />Rare side effects (may affect up to 1 in 1,000 people):<br />Feeling unwell, disturbances in consciousness, skin lumps (wheals), acute<br />kidney failure.<br />Some changes in blood test results have also been seen in rare cases and<br />include:<br />Rise in blood urea nitrogen, decrease in haemoglobin and haematocrit<br />values. Your doctor will know about these from a blood test and will tell<br />you if you need to do anything.<br />Further side effects reported with use of Olmesartan medoxomil or<br />Hydrochlorothiazide alone, but not with Olsar Plus&trade; or in a higher<br />frequency:<br />Olmesartan medoxomil:<br />Common side effects (may affect up to 1 in 10 people):<br />Bronchitis, cough, runny or stuffy nose, sore throat, abdominal pain,<br />indigestion, diarrhoea, nausea, gastroenteritis, pain in the joints or bones,<br />back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.<br />Some changes in blood test results have also been seen commonly and<br />include:<br />Rise in blood fat levels, rise in blood urea or uric acid, increase in levels of<br />liver and muscle function.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />Quick allergic reactions that may affect the whole body and may cause<br />breathing problems as well as a rapid fall of blood pressure that may even<br />lead to fainting (anaphylactic reactions), swelling of the face, angina (pain<br />or uncomfortable feeling in the chest; known as angina pectoris), feeling<br />unwell, allergic skin rash, itching, exanthema (skin eruption), skin lumps<br />(wheals).<br />Some changes in blood test results have also been seen uncommonly and<br />include: Reduced numbers of a type of blood cell, known as platelets<br />(thrombocytopenia).<br />Rare side effects (may affect up to 1 in 1,000 people):<br />Impaired kidney function, lack of energy.<br />Some changes in blood test results have also been seen rarely and include:<br />Increase in blood potassium.<br />Hydrochlorothiazide :<br />Very common side effects (may affect more than 1 in 10 people):<br />Changes in blood results including: Increase in blood fat and uric acid<br />levels.<br />Common side effects (may affect up to 1 in 10 people):<br />Feeling confused, abdominal pain, stomach upset, bloated feeling,<br />diarrhoea, nausea, vomiting, constipation, excretion of glucose into the<br />urine.<br />Some changes in blood results have also been seen and include:<br />Increase in blood creatinine, urea, calcium and sugar levels, decrease in<br />blood chloride, potassium, magnesium and sodium levels. Increase of<br />serum amylase (hyperamylasaemia).<br />Uncommon side effects (may affect up to 1 in 100 people):<br />Decreased or loss of appetite, severe difficulty breathing, anaphylactic skin<br />reactions (hypersensitivity reactions), worsening of pre-existing myopia<br />erythema, skin reactions to light, itching, purplish spots or patches on the<br />skin due to small haemorrhages (purpura), skin lumps (wheals).<br />Rare side effects (may affect up to 1 in 1,000 people):<br />Swollen and sore salivary glands, decreased number of white blood cells,<br />decreased number of blood platelets, anaemia, bone marrow damage,<br />restlessness, feeling &lsquo;down&rsquo; or depressed, problems sleeping, feeling<br />un-interested (apathy), tingling and numbness, fits (convulsions), objects<br />you look at appearing yellow , blurred vision, dry eyes, irregular heartbeat,<br />inflammation of the blood vessels, blood clots (thrombosis or embolism),<br />inflammation of the lung, fluid accumulation in the lungs, inflammation of<br />the pancreas, jaundice, infection in the gall bladder, symptoms of lupus<br />erythematosus (such as rash, joint pains and cold hands and fingers ) ,<br />allergic skin reactions , peeling and blistering of the skin, non- infectious<br />inflammation of the kidney (interstitial nephritis), fever, muscle weakness<br />(sometimes causing impaired movement).<br />Very rare side effects (may affect up to 1 in 10,000 people):<br />Electrolyte disturbance leading to an abnormally depleted level of chloride<br />in the blood (hypochloraemic alkalosis), blockage in the gut (paralytic<br />ileus).<br />Not known (frequency cannot be estimated from the available data):<br />Decrease in vision or eye pain (possible signs of acute angle-closure<br />glaucoma). Skin and lip cancer (Non-melanoma skin cancer).<br />Reporting of side effects:<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet. By reporting side effects<br />you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children.<br />Do not store above 30 &deg;C.<br />Do not use this medicine after the expiry date which is stated on the carton<br />and on the blister strip after EXP.<br />Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Olsar Plus&trade; contains:<br />The active substances are Olmesartan medoxomil and Hydrochlorothiazide.<br />Olsar Plus&trade; 20/12.5mg: Each film coated tablet contains 20 mg of<br />Olmesartan Medoxomil &amp; 12.5 mg of Hydrochlorothiazide.<br />Olsar Plus&trade; 40/12.5mg: Each film coated tablet contains 40 mg of<br />Olmesartan Medoxomil &amp; 12.5 mg of Hydrochlorothiazide<br />Olsar Plus&trade; 40/25mg: Each film coated tablet contains 40 mg of<br />Olmesartan Medoxomil &amp; 25 mg of Hydrochlorothiazide.<br />The other ingredients are:<br />Core: Lactose Monohydrate, Microcrystalline cellulose, Low substituted<br />Hydroxypropyl cellulose, Hydroxypropyl cellulose &amp; Magnesium Stearate.<br />Coating: Hypromellose, Hydroxypropyl cellulose, Titanium dioxide, talc<br />Yellow iron oxide and Red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Olsar Plus™ 20/12.5mg tablets are orange colored, circular, film coated
tablets with characteristic odour, debossed with "JP" on one side and "174"
on other side.
Olsar Plus™ 40/12.5mg tablets are orange colored, oblong, film coated
tablets with characteristic odour, debossed with "JP" on one side and "172"
on other side.
Olsar Plus™ 40/25mg tablets are pink colored, oblong, film coated tablets
with characteristic odour, debossed with "JP" on one side and "173"
on other side.
Olsar Plus™ 20/12.5mg film coated tablets are available in a box
of 28 tablets.
Olsar Plus™ 40/12.5mg film coated tablets are available in a box
of 28 tablets.
Olsar Plus™ 40/25mg film coated tablets are available in a box
of 28 tablets.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي أولسار بلس على مادّتين فعّالتين وهما أولميسارتان ميدوكسوميل وهيدروكلوروثيازيد</p><p>اللتان تُستخدمان لعلاج ارتفاع ضغط الدم .<br />&bull; يُعتبر أولميسارتان ميدوكسوميل واحدًا من مجموعة الأدوية التي تُسَمَّى مناهضات مستقبل<br />الأنجيوتنسين ۲. وتعمل على تقليل ضغط الدم عن طريق إرخاء الأوعية الدموية.<br />&bull; يُعتبر هيدروكلوروثيازيد واحدًا من مجموعة الأدوية التي تُسَمَّى مدرات البول الثيازيدية<br />(أقراص الماء). حيث يُخفض هذا العقار ضغط الدم من خلال مساعدة الجسم على التخلص من<br />السوائل الزائدة من خلال زيادة كمية البول التي تٌفرز عن طريق الكلى.<br />أولميسارتان ميدوكسوميل) وحده بكفاءة ) &trade; فقط إذا لم يتحكم أولسار &trade; سيتم وصف أولسار بلس<br />في ضغط الدم لديك.<br />على تقليل ضغط الدم &trade; عند تناولهما معًا، تساعد المادّتين الفعّالتين الموجودتين في أولسار بلس<br />أكثر مما لو تم تناول أيًا منهما بشكل منفرد.<br />قد تكون بالفعل تتناول أدوية لعلاج ارتفاع ضغط الدم، لكن قد يريد الطبيب المعالج لك أن تتناول<br />لتقليل بنسبة أكبر. &trade; أولسار بلس<br />أقراص. ومن المحتمل أن &trade; يمكن التحكم في ارتفاع ضغط الدم باستخدام أدوية أولسار بلس<br />يوصى الطبيب المعالج لك بإجراء بعض التغييرات في نمط حياتك للمساعدة على تقليل ضغط<br />الدم لديك (على سبيل المثال فقدان الوزن والإقلاع عن التدخين والحد من كمية الكحول التي<br />تشربها وتقليل كمية الملح في النظام الغذائي الخاص بك). وقد يشجعك الطبيب المعالج لك أيضًا<br />على ممارسة التمارين الرياضية بانتظام مثل المشي أو السباحة؛ ومن الهام اتباع هذه النصيحة<br />المقدّمة من الطبيب المعالج لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أولسار بلس في الحالات التالية:&nbsp;<br />&bull; إذا كنت تعاني من حساسية تجاه أولميسارتان ميدوكسوميل أو هيدروكلوروثيازيد أو تجاه أيّ<br />مكوّن من المكونات الأخرى الداخلة في تركيب هذا الدَّواء (المُدرجة في القسم رقم ٦) أو المواد<br />المشابهة لهيدروكلوروثيازيد (سلفوناميد).<br />في مراحل &trade; &bull; إذا كنتِ حاملًا منذ أكثر من ۳ أشهر (من الأفضل أيضًا تجنُّب تناوُل أولسار بلس<br />الحمل المُبكرة -انظري القسم الخاص ب &quot;الحمل&quot;).<br />&bull; إذا كنت تعاني من مشاكل بالكلى.<br />&bull; إذا كنت تعاني من مرض السكّري أو تعاني من قصور في وظائف الكُلى، ويتم علاجك بأحد<br />الأدوية الخافضة لضغط الدَّم التي تحتوي على &quot;أليسكيرين&quot;.<br />&bull; إذا كنت تعاني من انخفاض مستويات البوتاسيوم أو الصوديوم أو ارتفاع مستويات الكالسيوم<br />أو حمض اليوريك في الدم (مع وجود أعراض النقرس أو حصوات الكلى) التي لا تتحسن عند<br />معالجتها.<br />&bull; إذا كنت تعاني من مشاكل حادّة أو متوسطة في الكبد أو اصفرار في الجلد والعينين (يرقان) أو<br />مشاكل مع تصريف الصفراء من المرارة (انسداد القنوات الصفراوية مثل حصى المرارة).<br />إذا كنت تعتقد أن أي عرض من هذه الأعراض ينطبق عليك أو إذا كنت غير متأكدًا، فلا تقمْ<br />بتناول الأقراص. وتحدّث إلى الطبيب المعالج لك أولًا واتبع تعليماته.<br />تحذيرات واحتياطات<br />.&trade; تحدث إلى الطبيب المعالج لك قبل تناول أولسار بلس<br />قبل تناول الأقراص، أخبر الطبيب المعالج لك إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم<br />لعلاج ارتفاع ضغط الدَّم:<br />&bull; مثبط الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)،<br />على سبيل المثال إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري.<br />&bull; أليسكيرين<br />قد يُجري الطبيب المعالج لك فحصًا دورياً لوظائف الكُلى وضغط الدَّم لديك وكمية الكهارل<br />(مثل: البوتاسيوم) في الدَّم على فترات منتظمة. انظر أيضًا المعلومات تحت عنوان &quot;لا تتناول<br />.&trade; أولسار بلس<br />قبل تناول الأقراص، أخبر الطبيب المعالج لك إذا كنت تعاني من المشاكل الصحية الآتية:<br />&bull; خضعت لإجراء عملية زرع الكلى.<br />&bull; أمراض كبدية<br />&bull; فشل القلب أو مشاكل في صمامات أو عضلات القلب<br />&bull; قيء (إعياء) أو إسهال شديد أو مستمر لعدة أيام<br />&bull; إذا كنت تتناول جُرعات عالية من أقراص الماء (مدرّات البول) أو إذا كنت تتبع نظام غذائي<br />قليل الملح<br />&bull; مشاكل في الغدد الكظرية (مثل الألدوستيرونية الأولية)<br />&bull; مرض السُّكَّرِي.<br />&bull; الذئبة الحمامية (أحد أمراض المناعة الذاتية)<br />&bull; حساسية أو ربو.<br />&bull; إذا كنت قد عانيت مسبقًا من سرطان الجلد أو مرض جلدي غير متوقع أثناء فترة العلاج<br />قد يُزيد العلاج بهيدروكلوروثيازيد، خصوصًا العلاج طويل الأمد .&trade; باستخدام عقار أولسار بلس<br />بجرعات عالية، خطرَ الإصابة ببعض أنواع سرطان الجلد والشفاه (سرطان الجلد غير<br />الميلاني). قم بحماية جلدك من التعرض لأشعة الشمس والأشعة فوف البنفسجية أثناء تناول عقار<br />.&trade; أولسار بلس<br />أخبر الطبيب المعالج لك إذا شعرت بأيّ من الأعراض التالية:<br />&bull; إسهال حادّ مستديم والذي يسبب فقدانًا كبيرًا للوزن. قد يقوم الطبيب المعالج لك بتقييم<br />الأعراض واتخاذ قرار بشأن كيفية متابعة علاج ضغط الدم لديك.<br />&bull; إذا عانيت من انخفاض الرؤية أو ألم بالعين. حيث يمكن أن تكون هذه أعراض لزيادة ضغط<br />ويُمكِن أن يُؤدي .&trade; العين لديك وقد تحدث في غضون ساعات إلى أسابيع من تناول أولسار بلس<br />ذلك إلى ضعف البصر الدائم إذا لم يُعالَج.<br />قد يرغب الطبيب المعالج لك في رؤيتك في أغلب الأحيان، وإجراء بعض الفحوصات إذا كنت<br />تعاني من أيّ من هذه الحالات.<br />ارتفاعًا في مستويات الدهون في الدم ومستويات حمض اليوريك (سبب &trade; قد يسبب أولسار بلس<br />حدوث النقرس، تورّم مؤلم في المفاصل). فمن المحتمل أن يرغب الطبيب المعالج لك في إجراء<br />فحص دم لك من وقت لآخر للتحقق من ذلك.<br />قد تتغير مستويات بعض المواد الكيميائية في الدم والتي تسمى بالكهارل. فمن المحتمل أن يرغب<br />الطبيب المعالج لك في إجراء فحص دم لك من وقت لآخر للتحقق من ذلك. علامات تغيرات.<br />الكهارل هي: العطش، جفاف الفم، آلام أو تشنّجات العضلات، إرهاق العضلات، انخفاض<br />ضغط الدم (نقص ضغط الدم)، شعور بالضعف، كسل، تعب، نعاس أو تململ، غثيان، قيء، قلة<br />الحاجة للتبول، وسرعة معدّل ضربات القلب. أخبر الطبيب المعالج لك إذا لاحظت هذه<br />الأعراض.<br />كما هو الحال مع أي دواء يقلل من ضغط الدم، فإن الانخفاض الشديد في ضغط الدم لدى<br />المرضى الذين يعانون من اضطرابات في تدفق الدّم للقلب أو المخ قد يؤدي إلى حدوث نوبة<br />قلبية أو سكتة دماغية. لذلك، سيحتاج الطبيب المعالج لك إلى فحص ضغط الدَّم لديك بعناية.<br />إذا كان من المقرر إجراء تحاليل لفحص وظيفة الغدة الدرقية، فعليك التوقف عن تناول<br />قبل إجراء هذه الاختبارات. &trade; أولسار بلس<br />إذا كنت شخصًا رياضيًا فيمكن لهذا الدواء أن يعمل على تغيير نتائج اختبار مكافحة تناول<br />المنشطات بجعله إيجابيًا.<br />يجب عليكِ إخبار الطبيب المعالج لكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين) حاملًا. لا<br />في مراحل الحمل المبكرة أو إذا كنتِ حاملًا لأنه قد يسبب أضرارًا &trade; يُوصي بتناول أولسار بلس<br />خطيرة لطفلك (انظري القسم الخاص بذلك)<br />الأطفال والمراهقون<br />في المرضى من الأطفال والمراهقين الذين تقل أعمارهم &trade; لا يُوصى بتناول أولسار بلس<br />عن ۱۸ سنة.<br />مع أدوية أخرى: &trade; تناول أولسار بلس<br />يُرجى إبلاغ الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد<br />تتناول أيَّة أدوية أخرى.<br />على وجه الخصوص أخبر الطبيب المعالج لك أو الصيدلي الخاص بك عن تناولك أيًّا من الأدوية<br />التالية:<br />&bull; أدوية أخرى تستخدم لخفض ضغط الدم (خافضات ضغط الدم) حيث يمكنها زيادة تأثير أولسار<br />.&trade; بلس<br />قد يحتاج الطبيب المعالج لك إلى تغيير الجرعة الخاصة بك و/أو اتخاذ احتياطات أخرى في<br />الحالة التالية:<br />إذا كنت تتناول مثبط الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو أليسكيرين (انظر أيضًا المعلومات الواردة<br />و&quot;تحذيرات واحتياطات&quot;). &quot;&trade; أسفل العناوين: &quot;لا تتناول أولسار بلس<br />&bull; الأدوية التي قد تغير مستويات البوتاسيوم في الدم إذا تم تناولها في نفس وقت تناول<br />وتشمل ما يلي: &trade; أولسار بلس<br />- مكمّلات البوتاسيوم (بالإضافة إلى بدائل الملح التي تحتوي على البوتاسيوم).<br />- أقراص الماء (مدرّات البول).<br />- هيبارين (الذي يُستخدم لتخفيف الدّم).<br />- المُلَينات.<br />- الستيرويدات.<br />.(ACTH) - الهُرْمُونُ المُوَجِّهُ لقِشْرِ الكُظْر<br />- كاربنوكسولون (دواء يُتناول لعلاج قرحات الفم والمعدة).<br />- بنسلين جي الصوديوم. (ويسمى أيضا بنزيل بنسلين الصوديوم وهو مضاد حيوي)<br />- بعض مسكنات الألم مثل الأسبرين أو الساليسيلات<br />&bull; ليثيوم (دواء يُستَخدَم لعلاج تقلّبات المزاج وبعض أنواع الاكتئاب)، حيث قد يزيد أولسار بلس<br />من سمّية الليثيوم إذا تم استُخدمها في نفس الوقت. وإذا كان يجب عليك تناول الليثيوم، فسوف &trade;<br />يقوم الطبيب المعالج لك بقياس مستويات الليثيوم في الدم.<br />أدوية لتخفيف الألم والتورّم ) &quot;NSAIDs&quot; &bull; الأدوية المضادّة للالتهاب غير الستيرويدية<br />من خطر &trade; وأعراض الالتهاب الأخرى، بما في ذلك التهاب المفاصل) وقد يزيد أولسار بلس<br />بسبب &trade; الفشل الكلوي إذا تم استُخدمها في نفس الوقت ويمكن أن ينخفض تأثير عقار أولسار بلس<br />الأدوية المضادة للالتهاب غير الستيرويدية.<br />&bull; أقراص النوم والمهدئات والأدوية المضادة للاكتئاب، حيث قد يتسبب تناول هذه الأدوية<br />في حدوث انخفاض مفاجئ في ضغط الدم عند النهوض. &trade; بالتزامن مع أولسار بلس<br />&bull; بعض الأدوية مثل باكلوفين و توبوكورارين واللذان يُتناولان لإرخاء العضلات.<br />&bull; اميفوستين وبعض الأدوية الأخرى التي يتم تناولها لعلاج أمراض السرطان مثل<br />سيكلوفوسفاميد أو ميثوتركسيت.<br />&bull; كوليستيرامين وكوليستيبول وهما أدوية لخفض مستويات الدهون في الدم.<br />&bull; كوليسيفيلام هيدروكلوريد وهو دواء يقلل من مستوى الكوليسترول في الدم حيث قد يقلل من<br />قبل تناول كولسيفلام &trade; قد ينصحك الطبيب المعالج لك بتناول أولسار بلس .&trade; تأثير أولسار بلس<br />هيدروكلوريد بأربع ( ٤) ساعات على الأقل.<br />&bull; أدوية مضادة للكولين مثل عقار أتروبين و بيبيريدين.<br />&bull; أدوية مثل ثَيُوريدازين و كلُوربرُومازين و ليفوميبرومازين و ترايفلوبيرازين و سياميمازين و<br />سَلبيريد و أميسولبريد و بيموزيد و سولتوبريد وتيابريد ودُروبِيرِيدُول أو هالُوبِيرِيدُول التي<br />تُتناول لعلاج بعض الاضطرابات النفسية.<br />&bull; أدوية معينة مثل كينيدين و هيدروكيندين وديسوبيراميد و أميودارون و سوتالول أو ديجيتالس<br />التي تُتناول لعلاج مشاكل القلب.<br />&bull; أدوية مثل ميزولاستين و بنتاميدين و تيرفينادين و دوفتيليد و ابيوتيليد أو حقن إريثروميسين؛<br />التي تعمل على تغيير نبضات القلب لديك.<br />&bull; الأدوية المضادّة لداء السكّري التي تُتناول عن طريق الفم مثل ميتفورمين أو الأنسولين اللذان<br />يُتناولان لخفض نسبة السكر في الدم.<br />&bull; حاصرات بيتا و ديازوكسيد وهي أدوية تُتناول لعلاج ارتفاع ضغط الدم أو انخفاض نسبة<br />يمكنه تعزيز فاعلية زيادة نسبة السكر في &trade; السكر في الدم، على التوالي، حيث أن أولسار بلس<br />الدم.<br />&bull; ميثيل دوبا وهو دواء يستخدم في علاج ارتفاع ضغط الدم.<br />&bull; أدوية مثل نورادرينالين، التي يُتناول لزيادة ضغط الدم وإبطاء معدل ضربات القلب.<br />&bull; دوفيمانيل وهو دواء يُتناول لعلاج بطء ضربات القلب أو للحد من التعرّق.<br />&bull; أدوية مثل بروبينسيد و سولفينبيرازون و الوبيورينول (التي تُستخدم لعلاج النقرس).<br />&bull; المكملات الغذائية التي تحتوي على الكالسيوم.<br />&bull; أمانتادين، وهو دواء مضادّ للفيروسات.<br />&bull; سيكلوسبورين (دواء يُستخدم لمنع رفض الجسم للعضو المزروع).<br />&bull; بعض المضادّات الحيوية التي تسمى تيتراسايكلن أو سبارفلوكساسين.<br />&bull; أمفوتيريسين، وهو دواء يُتناول لعلاج حالات العدوى الفطرية.<br />&bull; مضادات حموضة معينة، والتي تُتناول لعلاج زيادة حمض المعدة بدرجة كبيرة للغاية مثل<br />هيدروكسيد الماغنسيوم. و هيدروكسيد الألومنيوم، حيث تعمل هذه الأدوية على خفض تأثير<br />قليلاً. &trade; أولسار بلس<br />&bull; سيسابريد (دواء يُتناول لزيادة حركة الطعام داخل المعدة والأمعاء).<br />&bull; هالوفنترين، دواء يُتناول لعلاج الملاريا.<br />مع الأغذية والمشروبات &trade; تناوُل أولسار بلس<br />مع الطعام أو بدونه. &trade; يمكن تناول أولسار بلس<br />حيث يشعر بعض الأشخاص ،&trade; كن على حذر عند شرب الكحول أثناء تناولك أولسار بلس<br />بإغماء أو بدوار. إذا حدث هذا لك، فلا تشرب أي كحول بما في ذلك النبيذ أو البيرة أو أي<br />مشروب خفيف يحتوي على الكحول.<br />المرضى أصحاب البشرة السوداء<br />على خفض ضغط الدّم أقل &trade; كما هو الحال مع الأدوية المشابهة الأخرى، فإن تأثير أولسار بلس<br />إلى حد ما لدى المرضى أصحاب البشرة السوداء.<br />الحَمْل والرّضاعة الطبيعية<br />الحمل<br />يجب عليكِ إخبار الطبيب المعالج لكِ إذا كنتِ تعتقدين أنكِ حاملاً (أو قد تصبحين) حاملًا.<br />قبل أن تصبحي حاملاً أو &trade; سينصحكِ الطبيب المعالج لكِ عادةً بالتوقف عن تناول أولسار بلس<br />.&trade; بمجرد أن تعلمي أنكِ حامل وسينصحكِ بتناول دواء آخر بدلًا من أولسار بلس<br />أثناء الحمل، ويجب عدم تناوُله إذا تجاوز حملكِ الشهر الثالث، &trade; لا ينصح بتناول أولسار بلس<br />حيث قد يُلحِق بِطفلك ضررًا خطيرًا إذا تم تناوله بعد الشهر الثالث من الحمل.<br />الرَّضاعة الطبيعية<br />أخبري الطبيب المعالج لكِ إذا كنتِ تُمارسين الرَّضاعة الطبيعية أو على وشك البدء في ممارسة<br />للأمهات اللواتي تمارسن الرضاعة &trade; الرَّضاعة الطبيعية. حيث لا يُوصى بتناول أولسار بلس<br />الطبيعية وقد يختار الطبيب المعالج لكِ علاجًا آخر إذا كنتِ ترغبين في ممارسة الرضاعة<br />الطبيعية.<br />إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية أو تعتقدين أنكِ حامل أو تخطِّطين لذلك،<br />فاستشيري الطبيب المعالج لكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء.<br />القيادة واستخدام الآلات<br />وذلك بسبب ارتفاع &trade; قد تشعر بنعاس أو دوار أثناء فترة العلاج باستخدام عقار أولسار بلس<br />ضغط الدم. فإذا حدث ذلك، فتجنَّب القيادة أو استخدام الآلات حتى تزول هذه الأعراض ويُرجى<br />استشارة الطبيب المعالج لك.<br />على اللاكتوز &trade; يحتوي أولسار بلس<br />يحتوي هذا الدَّواء على اللاكتوز (نوع من السكر). فإذا كان الطبيب المعالج لك قد أخبرك بأنك<br />لا تتحمّل بعض أنواع السكريات، فتحدّث إليه قبل تناول هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدَّواء تمامًا كما أخبرك الطبيب المعالج لك. واستشر الطبيب المعالج لك أو<br />الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناول.<br />٤۰ ملجم/ ۱۲٫٥ ملجم هي قرص واحد يوميًّا. ومع &trade; الجُرعة المُوصى بها من أولسار بلس<br />ذلك، إذا لم يتم التحكم في ضغط الدم لديك، قد يقرر الطبيب المعالج لك تغيير الجرعة إلى قرص<br />٤۰ ملجم/ ۲٥ ملجم يوميًا. &trade; واحد من أولسار بلس<br />قم بابتلاع القرص مع الماء. يجب أن تتناول الجرعة، إن كان ذلك ممكنًا، في نفس الموعد من<br />&trade; كل يوم؛ على سبيل المثال عند تناول الإفطار. ومن المهم الاستمرار في تناول أولسار بلس<br />مالم يطلب منك الطبيب المعالج لك التوقف عن تناوله.</p><p>إذا تناولت كمية أكثر مما يجب من أولسار بلس<br />إذا تناولت كمية من الأقراص أكثر مما يجب، أو ابتلع أحد الأطفال بعض الأقراص بطريق<br />الخطأ؛ يُرجى الذهاب إلي الطبيب المعالج لك أو التوجّه إلى أقرب قسم حوادث وطوارئ على<br />الفور وخذ معك علبة الدواء.<br />&trade; إذا أغفلت تناوُل أولسار بلس<br />إذا أغفلت تناول جرعة ما، قم بتناول الجرعة العادية في اليوم التالي كالمعتاد. ولا تتناول<br />جرعة مضاعفة لتعويض جرعة أغفلتها.<br />&trade; إذا توقفت عن تناول أولسار بلس<br />ما لم يطلب منك الطبيب المعالج لك التوقف عن &trade; من المهم الاستمرار في تناول أولسار بلس<br />تناوله.<br />إذا كانت لديك أيّة أسئلة إضافية حول تناول هذا الدواء، فاستشر الطبيب المعالج لك أو الصيدلي<br />الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يُسبب هذا الدَّواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لدى جميع<br />المرضى.<br />ومع ذلك، يمكن أن تكون الآثار الجانبية التالية خطيرة:<br />&bull; تفاعلات حساسية قد تؤثر على الجسم كله مصحوبة بتورم في الوجه والفم و/أو صندوق<br />الصوت (الحنجرة)، مع حكة وطفح جلدي نادرة الحدوث. فإذا حدث هذا لك، توقف عن تناول<br />واتصل بالطبيب المعالج لك على الفور. &trade; أولسار بلس<br />في انخفاض ضغط الدم بدرجة كبيرة جدًا لدي المرضى &trade; &bull; يمكن أن يتسبب أولسار بلس<br />المعرضين للإصابة به أو كنتيجة لرد فعل تحسسي. ووقعت الإصابة بدوار أو إغماء في<br />واتصل بالطبيب المعالج لك &trade; حالات غير شائعة. فإذا حدث ذلك، توقف عن تناول أولسار بلس<br />على الفور وقم بالاستلقاء بشكل مستو.<br />هو مزيج من مادتين فعّالتين والمعلومات التالية توضح أولًا الآثار الجانبية &trade; أولسار بلس<br />بالإضافة إلى تلك الآثار ) &trade; الأخرى التي تم الإبلاغ عنها حتى الآن مع تركيبة أولسار بلس<br />المذكورة سابقاً)، وثانياً تلك الآثار التي تظهر عادةً مع كل مادة من المادّتين الفعالتين بشكل<br />منفرد (كلٌّ على حدة)<br />:&trade; هذه هي الآثار الجانبية الأخرى التي تظهر عادة مع تناول أولسار بلس<br />وتعتبر تلك الآثار الجانبية، في أغلب الأحيان، خفيفة ولا تحتاج إلى إيقاف العلاج عند حدوثها.<br />آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى):<br />دوخة، ضعف، صداع، تعب، ألم بالصدر، تورم الكاحلين، القدمين، الساقين، اليدين أو<br />الذراعين.<br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض):<br />اضطراب نبضات القلب (خفقان)، طفح جلدي، إكزيما، دوار، سعال، عسر هضم، ألم في<br />البطن، غثيان، قيء، إسهال، تشنجات وألم في العضلات، ألم في المفاصل والذراعين<br />والساقين، آلام الظهر، مشاكل في الانتصاب لدى الرجال، ووجود دّم في البول.<br />قد لوحظ أيضاً بعض التغييرات في نتائج فحص الدم بشكل غير شائع وتشمل ما يلي:<br />ارتفاع مستويات الدهون في الدم، ارتفاع مستوى اليوريا أو حمض اليوريك في الدَّم أو ارتفاع<br />مستويات الكرياتينين أو ارتفاع أو انخفاض مستويات البوتاسيوم في الدم أو ارتفاع مستويات<br />الكالسيوم في الدم أو ارتفاع نسبة السكر في الدم أو زيادة مستويات وظائف الكبد. سيتحقق<br />الطبيب المعالج لك من ذلك من خلال فحص الدم وسيخبرك إذا كنت بحاجة إلى القيام بأي شيء<br />أم لا.<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰۰ مريض):<br />شعور بإعياء، اضطرابات في الوعي، تورم جلدي (بثور)، فشل كلوي حادّ.<br />قد لوحظ أيضًا بعض التغييرات في نتائج فحص الدم في حالات نادرة وتشمل مايلي:<br />زيادة تركيز نيتروجين اليوريا في الدم وانخفاض في نسب الهيموجلوبين والهيماتوكريت.<br />سيتحقق الطبيب المعالج لك من ذلك من خلال فحص الدم وسيخبرك إذا كنت بحاجة إلى القيام<br />بأي شيء أم لا.<br />قد تم الإبلاغ عن آثار جانبية إضافية تظهر عند تناول أولميسارتان ميدوكسوميل أو<br />أو مع &trade; هيدروكلوروثيازيد بشكل منفرد (كلٌّ على حدة)، ولكن ليس مع تناول أولسار بلس<br />كثرة التكرار:<br />أولميسارتان ميدوكسوميل:<br />آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى):<br />التهاب الشعب الهوائية، سعال، سيلان أو انسداد الأنف، التهاب الحلق، ألم بالبطن، عسر<br />الهضم، إِسْهال، غثيان، التهاب المعدة والأمعاء، آلام في المفاصل أو العظام، آلام الظهر،<br />وجود دَّم في البول، عدوى المسالك البولية، أعراض شبيهة بالأنفلونزا، وشعور بألم عام.<br />قد لوحظ أيضاً بعض التغييرات في نتائج فحص الدم بشكل شائع وتشمل ما يلي:<br />ارتفاع مستويات الدهون في الدم، ارتفاع مستويات اليوريا أو حمض اليوريك في الدّم، وزيادة<br />في مستويات وظائف الكبد والعضلات.<br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض):<br />تفاعلات حساسية سريعة قد تؤثر على الجسم كله وقد تسبب مشاكل في التنفس بالإضافة إلى<br />انخفاض سريع في ضغط الدم قد يؤدي إلى الإغماء، (تفاعلات تَأَقِيَّة)، تورم في الوجه، ذبحة<br />صدرية (ألم أو شعور غير مريح في الصدر وهو ما يُعرف بالذبحة الصدرية)، شعور بإعياء،<br />طفح جلدي تحسسي، حكة، طفح جلدي (تهيّج الجلد)، وتكيسات دهنية تحت الجلد (بثور).<br />قد لوحظ أيضاً بعض التغييرات في نتائج فحص الدم بشكل غير شائع وتشمل ما يلي:<br />انخفاض عدد أحد أنواع خلايا الدم المعروفة بالصفائح الدموية (نقص الصفائح الدموية).<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱,۰۰۰ مري ض ) :<br />قصور في وظائف الكلى ونقص أو فقدان لطاقة الجسم.<br />قد لوحظ أيضاً بعض التغييرات في نتائج فحص الدم بشكل نادر وتشمل ما يلي:<br />زيادة نسبة البوتاسيوم في الدم.<br />هيدروكلوروثيازيد:<br />آثار جانبية شائعة جدًّا (قد تُؤثر على أكثر من مريض واحد من بين كل ۱۰ مرضى):<br />تغيُّرات في نتائج فحص الدم وتشمل ما يلي: زيادة مستويات الدهون وحمض اليوريك في الدَّم.<br />آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى):<br />شعور بالارتباك، ألم في البطن، اضطراب في المعدة، شعور بالانتفاخ، إسهال، غثيان، قيء،<br />إمساك، إفراز الجلوكوز في البول.<br />قد لوحظ أيضًا بعض التغييرات في نتائج فحص الدم وتشمل ما يلي:<br />زيادة في مستويات الكرياتينين و اليوريا و الكالسيوم و مستويات السكر في الدم، انخفاض في<br />مستويات الكلوريد والبوتاسيوم الماغنسيوم. ومستويات الصوديوم في الدم. زيادة تركيز أميلاز<br />المصل (فَرْطُ أَميلاَزِ الدَّم).<br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض):<br />انخفاض أو فقدان الشهية، صعوبة شديدة في التنفس، تفاعلات الجلد التأقية (تفاعلات فرط<br />التحسس)، تفاقم حالة قصر النظر الموجود مسبقًا، حُمامى (احمرار والتهاب الجلد)، تفاعلات<br />جلدية تجاه الضوء، حكة، ظهور بقع أرجوانية على الجلد نتيجة حدوث نزف دموي صغير<br />(فُرْفُرِيَّة أو ما يُعرف بالطفح الجلدي النزفي)، وتكيسات دهنية تحت الجلد (بثور).<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱,۰۰۰ مريض):<br />تورّم وإيلام الغدد اللعابية، انخفاض عدد خلايا الدم البيضاء، انخفاض عدد الصفائح الدموية،<br />أنيميا &quot;فقر الدم&quot;، تلف النخاع العظمي، تململ، شعور بإحباط أو اكتئاب، مشاكل في النوم،<br />شعور باللامبالاة (فتور الشعور أو الخمول)، وخز و تنميل، نوبات (تشنّجات)، ظهور الأشياء<br />باللون الأصفر عند النظر إليها، تغيُّم الرؤية، جفاف العين، عدم انتظام ضربات القلب، التهاب<br />الأوعية الدموية، تجلطات الدم (تخثر أو انسداد الدم)، التهاب الرئة، تجمع السوائل في<br />الرئتين، التهاب البنكرياس، يرقان، عدوى المرارة، ظهور أعراض الذئبة الحمامية (مثل طفح<br />جلدي، آلام المفاصل، برودة اليدين والأصابع)، تفاعلات جلدية حساسية، تقشر وبثور الجلد،<br />التهاب الكلى غير المعدي (التهاب الكلى الخِلاليّ)، حُمى، وضعف في العضلات (الذي يُسبب<br />أحيانًا صعوبات أثناء الحركة).<br />آثار جانبية نادرة جدًّا (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰,۰۰۰<br />مريض):<br />اضطراب الكهارل الذي يؤدي إلى مستوى منخفض من الكلوريد في الدم بشكل غير طبيعي<br />(قلوية ناتجة عن نقص كلوريد الدَّم)، انسداد في القناة الهضمية (علوص شللي &quot;انسداد الأمعاء<br />نتيجة لحدوث شلل في عضلات الأمعاء&quot;).<br />آثار جانبية غير معروف معدّل تكرارها (لا يمكن تقدير معدّل التكرار من واقع البيانات<br />المتاحة):<br />انخفاض الرؤية وألم بالعينين (علامات مُحتَمَلة للإصابة بزَرَق انسداد الزاوية الحادّ)، سرطان<br />الجلد والشفاه (سرطان الجلد غير الميلانيني).<br />الإبلاغ عن الآثار الجانبية:<br />إذا أصبت بأيَّة آثار جانبية، تحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك. ويشمل ذلك<br />أيّة آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. يمكنك المساعدة في توفير معلومات<br />إضافية حول أمان استخدام هذا الدَّواء من خلال إبلاغك عن آثار جانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن مُتناوَل و مرأى الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تستخدم هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدوّن على العبوة الكرتونية والشريط بعد<br />.&quot;EXP&quot; كلمة<br />لا تقم بالتخلّص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلّفات المنزلية.<br />استشر الصيدلي الخاص بك حول كيفية التَّخلص من الأدوية التي لم تعد تحتاج إليها. حيث<br />تُساعد هذه التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olsar Plus 40/25 film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablets contains 40 mg of Olmesartan Medoxomil and 25 mg Hydrochlorothiazide.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets:

Pink colored, oblong, film coated tablets with characteristic odour, debossed with "JP" on one side and "173"on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p>&nbsp;</p><p>Olmesartan Medoxomil and Hydrochlorothiazide fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults</p><p>The recommended dose of Olsar Plus 40 mg/12.5 mg or 40 mg/25 mg is 1 tablet per day.</p><p>Olsar Plus 40 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by olmesartan medoxomil 40 mg alone.</p><p>Olsar Plus 40 mg/25 mg may be administered in patients whose blood pressure is not adequately controlled on Olsar Plus 40 mg/12.5 mg fixed dose combination.</p><p>For convenience, patients receiving olmesartan medoxomil and hydrochlorothiazide from separate tablets may be switched to Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg tablets containing the same component doses.</p><p>Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg can be taken with or without food.</p><p>&nbsp;</p><p>Elderly (age 65 years or over)</p><p>In elderly people the same dosage of the combination is recommended as for adults.</p><p>Blood pressure should be closely monitored.</p><p>Renal impairment:</p><p>Olsar Plus is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min).</p><p>The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30 &ndash; 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group, and periodic monitoring is advised.</p><p>Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg is therefore contraindicated in all stages of renal impairment (see sections 4.3, 4.4, 5.2).</p><p>Hepatic impairment:</p><p>Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg should be used with caution in patients with mild hepatic impairment (see sections 4.4, 5.2). Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are receiving diuretics and/or other antihypertensive agents. In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment. Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg therefore should not be used in patients with moderate and severe hepatic impairment (see sections 4.3, 5.2), as well as in cholestasis and biliary obstruction (see section 4.3).</p><p>Paediatric population:</p><p>The safety and efficacy of Olsar Plus 40 mg/12.5 mg and 40 mg/25 mg in children and adolescents below 18 years has not been established. No data are available.</p><p><u>Method of administration</u></p><p>The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to other sulfonamide-derived substances (since hydrochlorothiazide is a sulfonamide-derived medicinal product).
Severe renal impairment (creatinine clearance < 30 mL/min).
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Severe hepatic impairment, cholestasis and biliary obstructive disorders.
2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).
The concomitant use of Olmesartan Medoxomil and Hydrochlorothiazide with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Intravascular volume depletion:</strong></p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Olmesartan Medoxomil and Hydrochlorothiazide.</p><p><strong>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</strong></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p><strong>Renovascular hypertension:</strong></p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.</p><p><strong>Renal impairment and kidney transplantation:</strong></p><p>Olmesartan Medoxomil and Hydrochlorothiazide should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see section 4.3). No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance is &ge; 30 mL/min, &lt; 60 mL/min). However, in such patients Olmesartan Medoxomil and Hydrochlorothiazide should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy. There is no experience of the administration of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;in patients with a recent kidney transplantation.</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Hepatic impairment:</strong></p><p>There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease. Therefore care should be taken in patients with mild to moderate hepatic impairment (see section 4.2). Use of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;in patients with severe hepatic impairment, cholestasis and biliary obstruction is contraindicated (see sections 4.3, 5.2).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:</strong></p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><strong>Primary aldosteronism:</strong></p><p>Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;is not recommended in such patients.</p><p><strong>Metabolic and endocrine effects:</strong></p><p>Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.</p><p>Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.</p><p>Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p><strong>&nbsp;</strong></p><p><strong>Electrolyte imbalance:</strong></p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).</p><p>The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).</p><p>Conversely, due to antagonism at the angiotensin-II receptors (AT<sub>1</sub>) through the olmesartan medoxomil component of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes and other medicinal products that may increase serum potassium levels (e.g. heparin) should be co-administered cautiously with Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;(see section 4.5).</p><p>There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p><strong>&nbsp;</strong></p><p><strong>Lithium:</strong></p><p>As with other medicinal products containing angiotensin II receptor antagonists and thiazide in combination, the coadministration of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;and lithium is not recommended (see section 4.5).</p><p><strong>Sprue-like enteropathy:</strong></p><p>In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.</p><p><strong>Acute Myopia and Secondary Angle-Closure Glaucoma:</strong></p><p>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><strong>&nbsp;</strong></p><p><strong>Non-melanoma skin cancer:</strong></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.</p><p>Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p><p><strong>Ethnic differences:</strong></p><p>As with all other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p><strong>&nbsp;</strong></p><p><strong>Anti-doping test:</strong></p><p>Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.</p><p><strong>Pregnancy:</strong></p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6)</p><p><strong>&nbsp;</strong></p><p><strong>Other:</strong></p><p>In general arteriosclerosis, in patients with ischaemic heart disease or ischaemic cerebrovascular disease, there is always a risk that excessive blood pressure decrease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics. This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential interactions related to both olmesartan medoxomil and hydrochlorothiazide:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>Lithium:</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II receptor antagonists. In addition, renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be increased. Therefore use of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><em>Baclofen:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Non-steroidal anti-inflammatory medicinal products:</em></p><p>NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists.</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly people with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in elderly people. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.</p><p><strong><em>Concomitant use to be taken into account</em></strong></p><p><em>Amifostine:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Other antihypertensive agents:</em></p><p>The blood pressure lowering effect of Olmesartan Medoxomil and Hydrochlorothiazide can be increased by concomitant use of other antihypertensive medicinal products.</p><p><em>Alcohol, barbiturates, narcotics or antidepressants:</em></p><p>Potentiation of orthostatic hypotension may occur.</p><p><strong>Potential interactions related to olmesartan medoxomil:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>ACE-inhibitors, angiotensin II receptor blockers or aliskiren:</em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em>Medicinal products affecting potassium levels:</em></p><p>Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal products which affect potassium levels are to be prescribed in combination with Olmesartan Medoxomil and Hydrochlorothiazide , monitoring of potassium plasma levels is advised.</p><p><em>Bile acid sequestering agent colesevelam:</em></p><p>Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered (see section 5.2).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Additional information</em></strong></p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4&nbsp;<em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p><strong>Potential interactions related to hydrochlorothiazide</strong>:</p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>Medicinal products affecting potassium levels:</em></p><p>The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by the coadministration of other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is therefore not recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><em>Calcium salts:</em></p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.</p><p><em>Cholestyramine and colestipol resins:</em></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><em>Digitalis glycosides:</em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p><em>Medicinal products affected by serum potassium disturbances:</em></p><p>Periodic monitoring of serum potassium and ECG is recommended when Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>- Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).</p><p>- Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>- Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).</p><p>- Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV).</p><p><em>Non-depolarizing skeletal muscle relaxants (e.g. tubocurarine):</em></p><p>The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><em>Anticholinergic agents (e.g. atropine, biperiden):</em></p><p>Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><em>Antidiabetic medicinal products (oral agents and insulin):</em></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).</p><p><em>Metformin:</em></p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta-blockers and diazoxide:</em></p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><em>Pressor amines (e.g. noradrenaline):</em></p><p>The effect of pressor amines may be decreased.</p><p><em>Medicinal products used in the treatment of gout (e.g. probenecid, sulfinpyrazone and allopurinol)</em>:</p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><em>Amantadine:</em></p><p>Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><em>Cytotoxic agents (e.g. cyclophosphamide, methotrexate):</em></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><em>Salicylates:</em></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><em>Methyldopa:</em></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><em>Cyclosporine:</em></p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p><em>Tetracyclines:</em></p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced increase in urea. This interaction is probably not applicable to doxycycline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy (see section 4.3)</u></p><p>Given the effects of the individual components in this combination product on pregnancy, the use of Olmesartan Medoxomil and Hydrochlorothiazide is not recommended during the first trimester of pregnancy (see section 4.4). The use of Olmesartan Medoxomil and Hydrochlorothiazide is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p><em>Olmesartan medoxomil:</em></p><p>The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II receptor antagonists therapy during the 2nd and 3rd trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &ldquo;Preclinical safety data&rdquo;.)</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Hydrochlorothiazide:</em></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p><u>Breast-feeding</u></p><p><em>Olmesartan medoxomil:</em></p><p>Because no information is available regarding the use of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;during breast-feeding, Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production.</p><p>The use of Olmesartan Medoxomil and Hydrochlorothiazide during breast-feeding is not recommended. If Olmesartan Medoxomil and Hydrochlorothiazide is used during breast-feeding, doses should be kept as low as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmesartan Medoxomil and Hydrochlorothiazide has minor or moderate influence on the ability to drive and use machines. Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions during treatment with Olmesartan Medoxomil and Hydrochlorothiazide are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).</p><p>Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance (see section 4.4).</p><p>In clinical trials involving 1155 patients treated with olmesartan medoxomil/ hydrochlorothiazide combinations at dosages of 20/12.5 mg or 20/25 mg and 466 patients treated with placebo for periods of up to 21 months, the overall frequency of adverse reactions on olmesartan medoxomil/hydrochlorothiazide combination therapy was similar to that on placebo. Discontinuations due to adverse reactions were also similar for olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg - 20/25 mg (2%) and placebo (3%). The frequency of adverse reactions on olmesartan medoxomil/ hydrochlorothiazide overall relative to placebo appeared to be unrelated to age (&lt; 65 years versus &ge; 65 years), gender or race although the frequency of dizziness was somewhat increased in patients aged &ge; 75 years.</p><p>In addition, the safety of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;as a high dose combination was investigated in clinical trials in 3709 patients receiving olmesartan medoxomil in combination with hydrochlorothiazide in the dose strengths 40 mg/12.5 mg and 40 mg/25 mg.</p><p>Adverse reactions from Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and hydrochlorothiazide based on the known safety profile of these substances.</p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA</p><p>System Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reactions</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Olmesartan Medoxomil and Hydrochlorothiazide</p></td><td style="vertical-align:top"><p>Olmesartan</p></td><td style="vertical-align:top"><p>HCTZ</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/ Agranulocytosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glykosuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alcalosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypokaliaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disturbances</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Disturbances in consciousness (such as loss of consciousness)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dizziness/light-headedness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Transient blurred vision</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of pre-existing myopia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Acute myopia, acute angle-closure glaucoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Necrotising angiitis (vasculitis, cutaneous vasculitis)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial pneumonia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="12" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sprue-like enteropathy (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestasic icterus)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Anaphylactic skin reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematodes-like reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exanthem</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal dysfunction</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood calcium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood glucose increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood haematocrit decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood haemoglobin decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood lipids increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea nitrogen increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gamma glutamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.</p><p>Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222,</p><p>Exts: 2317-2356-2340.</p><p>Toll free phone: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&nbsp; <strong>&bull; Other GCC States:</strong></p><p>&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the effects or treatment of Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;overdose. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.</p><p>&nbsp;</p><p>The most likely manifestations of olmesartan medoxomil overdose are expected to be hypotension and tachycardia; bradycardia might also occur. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.</p><p>&nbsp;</p><p>No information is available regarding the dialysability of olmesartan or hydrochlorothiazide.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code: C09DA08.</p><p>Mechanism of action / Pharmacodynamic effects</p><p>Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p>Once daily dosing with Olmesartan Medoxomil and Hydrochlorothiazide &nbsp;provides an effective and smooth reduction in blood pressure over the 24 hour dose interval.</p><p>Olmesartan medoxomil is an orally active, selective angiotensin II receptor (type AT1) antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1 receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>&nbsp;</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.</p><p>The effect of olmesartan medoxomil on mortality and morbidity is not yet known.</p><p>The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.</p><p>For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.</p><p>For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.</p><p>The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.</p><p>Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.</p><p>&nbsp;</p><p>Clinical efficacy and safety</p><p>The combination of olmesartan medoxomil and hydrochlorothiazide produces additive reductions in blood pressure which generally increase with the dose of each component. In pooled placebo-controlled studies, administration of the 20 /12.5 mg and 20 /25 mg combinations of olmesartan medoxomil/hydrochlorothiazide resulted in mean placebo-subtracted systolic/diastolic blood pressure reductions at trough of 12/7 mmHg and 16/9 mmHg, respectively. Age and gender had no clinically relevant effect on response to treatment with olmesartan medoxomil/hydrochlorothiazide combination therapy.</p><p>Administration of 12.5 mg and 25 mg hydrochlorothiazide in patients insufficiently controlled by olmesartan medoxomil 20 mg monotherapy gave additional reductions in 24-hour systolic/diastolic blood pressures measured by ambulatory blood pressure monitoring of 7/5 mmHg and 12/7 mmHg, respectively, compared with olmesartan medoxomil monotherapy baseline. The additional mean systolic/diastolic blood pressure reductions at trough compared with baseline, measured conventionally, were 11/10 mmHg and 16/11 mmHg, respectively.</p><p>The effectiveness of olmesartan medoxomil/hydrochlorothiazide combination therapy was maintained over long-term (one-year) treatment. Withdrawal of olmesartan medoxomil therapy, with or without concomitant hydrochlorothiazide therapy, did not result in rebound hypertension.</p><p>The effects of fixed dose combination of olmesartan medoxomil/hydrochlorothiazide on mortality and cardiovascular morbidity are currently unknown.</p><p>&nbsp;</p><p>Other information:</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p>Non-melanoma skin cancer:</p><p>Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High HCTZ use (&ge;50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip-cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption and distribution</p><p>Olmesartan medoxomil:</p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>&nbsp;</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p>&nbsp;</p><p>Hydrochlorothiazide:</p><p>Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing. Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 &ndash; 1.14 L/kg.</p><p>&nbsp;</p><p>Biotransformation and elimination</p><p>Olmesartan medoxomil:</p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p>&nbsp;</p><p>Hydrochlorothiazide:</p><p>Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60% of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250 &ndash; 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 &ndash; 15 hours.</p><p>&nbsp;</p><p>&nbsp;</p><p>Olmesartan Medoxomil and Hydrochlorothiazide</p><p>The systemic availability of hydrochlorothiazide is reduced by about 20% when co-administered with olmesartan medoxomil, but this modest decrease is not of any clinical relevance. The kinetics of olmesartan are unaffected by the co-administration of hydrochlorothiazide.</p><p>&nbsp;</p><p>Pharmacokinetics in special populations</p><p>Elderly (age 65 years or over):</p><p>In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly people (65 &ndash; 75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with the younger age group (see section 4.2).</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly people compared to young healthy volunteers.</p><p>&nbsp;</p><p>Renal impairment:</p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.4).</p><p>The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.</p><p>&nbsp;</p><p>Hepatic impairment:</p><p>After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values were similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).</p><p>&nbsp;</p><p>Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide.</p><p>&nbsp;</p><p>Drug interactions</p><p>Bile acid sequestering agent colesevelam:</p><p>Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxic potential of olmesartan medoxomil/hydrochlorothiazide combinations was evaluated in repeated dose oral toxicity studies for up to six months in rats and dogs.</p><p>As for each of the individual substances and other medicinal products in this class, the main toxicological target organ of the combination was the kidney. The combination of olmesartan medoxomil/hydrochlorothiazide induced functional renal changes (increases in serum urea nitrogen and in serum creatinine). High dosages caused tubular degeneration and regeneration in the kidneys of rats and dogs, probably via a change in renal haemodynamics (reduced renal perfusion resulting from hypotension with tubular hypoxia and tubular cell degeneration). In addition, the olmesartan medoxomil/ hydrochlorothiazide combination caused a decrease in red blood cell parameters (erythrocytes, haemoglobin and haematocrit) and a reduction in heart weight in rats.</p><p>These effects have also been observed for other AT1 receptor antagonists and for ACE inhibitors and they seem to have been induced by the pharmacological action of high dosages of olmesartan medoxomil and seem to be not relevant to humans at the recommended therapeutic doses.</p><p>Genotoxicity studies using combined olmesartan medoxomil and hydrochlorothiazide as well as the individual components have not shown any signs of a clinically relevant genotoxic activity.</p><p>The carcinogenic potential of a combination of olmesartan medoxomil and hydrochlorothiazide was not investigated as there was no evidence of relevant carcinogenic effects for the two individual components under conditions of clinical use.</p><p>There was no evidence of teratogenicity in mice or rats treated with olmesartan medoxomil/hydrochlorothiazide combinations. As expected from this class of medicinal product, fetal toxicity was observed in rats, as evidenced by significantly reduced fetal body weights, when treated with olmesartan medoxomil/hydrochlorothiazide combinations during gestation (see sections 4.3, 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>&nbsp;</p><p>Lactose Monohydrate</p><p>Lactose Monohydrate Super tab 11 SD</p><p>Microcrystalline Cellulose</p></td></tr><tr><td><p>Low Subs. Hydroxypropyl Cellulose</p><p>Hydroxypropyl Cellulose</p><p>Magnesium Stearate</p></td></tr><tr><td><p>Opadry Orange (used in 20/12.5 mg and 40/12.5 mg strength)</p><p>Opadry Pink (used in 40/25 mg strength)</p><p>Purified water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blister pack</p><p>Pack sizes: 4 X 7&rsquo;s tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company 
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep-2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>